Generation of tumor-specific t lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28

Journal of Immunotherapy

Volumn 33, Issue 2, 2010, Pages 155-166

  Rosenblatt, Jacalyn ^a   Wu, Zekui ^b   Vasir, Baldev ^b   Zarwan, Corrine ^a   Stone, Richard ^b   Mills, Heidi ^a   Friedman, Thea ^c   Konstantinopoulos, Panagiotis A ^a   Spentzos, Dimitrios ^a   Ghebremichael, Musie ^b   Stevenson, Kristen ^b   Neuberg, Donna ^b   Levine, James D ^a   Joyce, Robin ^a   Tzachanis, Dimitrios ^a   Boussiotis, Vassiliki ^a   Kufe, Donald ^b   Avigan, David ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Dana Farber Cancer Institute   (United States)

^c HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adoptive immunotherapy; Dendritic cell tumor fusion vaccine; Educated T cell

Indexed keywords

ANTIBODY; CANCER VACCINE; CD28 ANTIBODY; CD3 ANTIBODY; CD69 ANTIGEN; GAMMA INTERFERON; GRANZYME B; MUCIN 1; T LYMPHOCYTE VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ARTICLE; CELL EXPANSION; CELL FUSION; CYTOKINE PRODUCTION; DENDRITIC CELL; GENE EXPRESSION; LYMPHOCYTE PROLIFERATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL DESTRUCTION; UPREGULATION;

ANTIGEN PRESENTATION; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; CANCER VACCINES; CELL FUSION; CELL PROLIFERATION; CLONE CELLS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; GENES, T-CELL RECEPTOR BETA; GRANZYMES; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MUCIN-1; T-LYMPHOCYTES;

EID: 77649122698     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181bed253     Document Type: Article

References (35)

1. Speiser DE, Miranda R, Zakarian A, et al. Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med. 1997;186:645-653.
2. Gabrilovich DI, Corak J, Ciernik IF, et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res. 1997;3:483-490.
3. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol. 2005;6:338-344.
4. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adeno-carcinoma. J Immunol. 2002;169:2756-2761.
5. Avigan D. Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Rev. 1999;13:51-64.
6. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood. 2004;104:2235-2246.
7. Gong J, Chen D, Kashiwaba M, et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med. 1997;3:558-561. (Pubitemid 27198656)
8. Gong J, Chen D, Kashiwaba M, et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA. 1998;95:6279-6283.
9. Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res. 2004; 10:4699-4708.
10. Avigan D, George DJ, Kantoff PW, et al. Interim safety and efficacy results from a phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Clin Oncol ASCO Annu Meet Proc. 2004;22:169.
11. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 2007;117:1466-1476.
12. June CH. Principles of adoptive T cell cancer therapy. J Clin Invest. 2007;117:1204-1212.
13. Knutson KL, Wagner W, Disis ML. Adoptive T cell therapy of solid cancers. Cancer Immunol Immunother. 2006;55:96-103.
14. Zhou J, Dudley ME, Rosenberg SA, et al. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother. 2005;28:53-62.
15. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopula-tion with antitumor lymphocytes. Science. 2002;298:850-854.
16. Robbins PF, Dudley ME, Wunderlich J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 2004;173:7125-7130.
17. Bonyhadi M, Frohlich M, Rasmussen A, et al. In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia. J Immunol. 2005;174: 2366-2375.
18. Wang D, Matsumoto R, You Y, et al. CD3/CD28 costimula-tion-induced NF-kappaB activation is mediated by recruitment of protein kinase C-theta, Bcl10, and IkappaB kinase beta to the immunological synapse through CARMA1. Mol Cell Biol. 2004;24:164-171.
19. Herndon TM, Shan XC, Tsokos GC, et al. ZAP-70 and SLP-76 regulate protein kinase C-theta and NF-kappa B activation in response to engagement of CD3 and CD28. J Immunol. 2001;166:5654-5664.
20. Kalamasz D, Long SA, Taniguchi R, et al. Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies. J Immunother. 2004;27:405-418.
21. Jung U, Foley JE, Erdmann AA, et al. CD3/CD28-costimu-lated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects. Blood. 2003;102: 3439-3446.
22. Gong J, Avigan D, Chen D, et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA. 2000;97: 2715-2718. (Pubitemid 30159237)
23. Gong J, Nikrui N, Chen D, et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol. 2000;165: 1705-1711. (Pubitemid 30604610)
24. Friedman TM, Goldgirsh K, Berger SA, et al. Overlap between in vitro donor antihost and in vivo posttransplantation TCR Vbeta use: a new paradigm for designer allogeneic blood and marrow transplantation. Blood. 2008;112:3517-3525.
25. Pavlidis P, Qin J, Arango V, et al. Using the gene ontology for microarray data mining: a comparison of methods and application to age effects in human prefrontal cortex. Neurochem Res. 2004;29:1213-1222.
26. Lespagnard L, Mettens P, Verheyden AM, et al. Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int J Cancer. 1998;76:250-258.
27. Khoshnan A, Bae D, Tindell CA, et al. The physical association of protein kinase C theta with a lipid raft-associated inhibitor of kappa B factor kinase (IKK) complex plays a role in the activation of the NF-kappa B cascade by TCR and CD28. J Immunol. 2000;165:6933-6940.
28. Yamada-Ohnishi Y, Azuma H, Urushibara N, et al. Cytotoxic difference of T cells expanded with anti-CD3 monoclonal antibody in the presence and absence of anti-CD 28 monoclonal antibody. Stem Cells Dev. 2004;13:315-322.
29. Lin SJ, Cheng PJ, Hsiao SS. Effect of interleukin-15 on effector and regulatory function of anti-CD3/anti-CD28-stimulated CD4(+) T cells. Bone Marrow Transplant. 2006;37:881-887.
30. Hughes DP, Baskar D, Urban FF, et al. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo. Cytotherapy. 2005;7:396-407.
31. Bernstein WB, Cox JH, Aronson NE, et al. Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4(+) T cells to HIV-infected persons. Clin Immunol. 2004;111:262-274.
32. Thompson JA, Figlin RA, Sifri-Steele C, et al. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2003;9:3562-3570.1.
33. Porter DL, Levine BL, Bunin N, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/ CD28 costimulation. Blood. 2006;107:1325-1331.
34. Rapoport AP, Stadtmauer EA, Aqui N, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med. 2005;11:1230-1237.
35. Dang Y, Knutson KL, Goodell V, et al. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming. Clin Cancer Res. 2007;13:1883-1891.